Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal...
Company Valuation
Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.
Target Price
The average target price of ATRA is 8.8 and suggests 58% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell